VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA) - GlobeNewswire

VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA)  GlobeNewswire

TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases